Chimeric antigen receptor (CAR) T cell therapy is an immunotherapy. It uses a patient’s own immune system to fight certain blood cancers. Normal T cells can “hook” onto cancer cells and kill them, but ...

Liso-Cel is a type of CAR T-cell therapy — a revolutionary approach that uses a patient's own immune cells to fight cancer.

To date, the Food and Drug Administration (FDA) has approved seven chimeric antigen receptor-T (CAR-T) cell therapies and seven bispecific T-cell engagers (BiTEs) across a variety of hematologic ...

A new paper from MUSC Hollings Cancer Center researchers is helping to reveal the "rules" for engineering chimeric antigen receptor (CAR) Tregs. Tregs, or T-regulatory cells, have shown promise in ...

USC researchers have developed an innovative type of cancer-fighting immune cell, the EchoBack CAR T-cell, that uses focused ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing their ability to infiltrate solid tumours.

bound to Cas9-RNP, is then delivered to cells to promote precise knock-in via homology-directed repair. This method significantly enhances the precision and efficiency of CAR T cell production.

During a live event, Nathan M. Denlinger, DO, MS, discussed the TRANSFORM trial of lisocabtagene maraleucel in B-cell ...

Chimeric antigen receptor (CAR-T) cell therapy is a rapidly growing frontier in cancer research, with Australian biotech ...